Clinical trialNCT05061550RecruitingPhase 2Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

SponsorAstraZenecaEnrollment630Non-small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tina Cascone, MD
MD Anderson Cancer Center Houston, TX 77030
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

97 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Research Site
Ghent, Belgium
Completed
Research Site
Ghent, Belgium
Recruiting
Research Site
Roeselare, Belgium
Recruiting

Canada

Research Site
Edmonton, Alberta, Canada
Completed
Research Site
Winnipeg, Manitoba, Canada
Recruiting
Research Site
Montreal, Quebec, Canada
Recruiting
Research Site
Montreal, Quebec, Canada
Recruiting

France

Research Site
Avignon, France
Recruiting
Research Site
Bobigny, France
Withdrawn
Research Site
Bordeaux, France
Recruiting
Research Site
Limoges, France
Recruiting
Research Site
Rennes, France
Recruiting
Research Site
Rouen, France
Recruiting
Research Site
Suresnes, France
Recruiting
Research Site
Toulon, France
Recruiting

Hungary

Research Site
Kecskemét, Hungary
Recruiting
Research Site
Székesfehérvár, Hungary
Recruiting
Research Site
Tatabánya, Hungary
Completed
Research Site
Törökbálint, Hungary
Recruiting

Ireland

Research Site
Dublin, Ireland
Recruiting
Research Site
Dublin, Ireland
Recruiting
Research Site
Dublin, Ireland
Recruiting
Research Site
Galway, Ireland
Recruiting

Italy

Research Site
Aviano, Italy
Recruiting
Research Site
Brescia, Italy
Recruiting
Research Site
Catanzaro, Italy
Withdrawn
Research Site
Florence, Italy
Recruiting
Research Site
Genova, Italy
Recruiting
Research Site
Meldola, Italy
Recruiting
Research Site
Milan, Italy
Recruiting
Research Site
Monza, Italy
Recruiting
Research Site
Padova, Italy
Recruiting
Research Site
Perugia, Italy
Recruiting
Research Site
Pisa, Italy
Recruiting
Research Site
Roma, Italy
Recruiting
Research Site
Rozzano, Italy
Recruiting

Portugal

Research Site
Lisbon, Portugal
Recruiting
Research Site
Lisbon, Portugal
Recruiting
Research Site
Lisbon, Portugal
Recruiting
Research Site
Lisbon, Portugal
Recruiting

57 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD0171Carboplatin →Cisplatin →Dato-DXdDurvalumab →MonalizumabOleclumabPemetrexed →RilvegostomigVolrustomig

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Apr 2022
Primary completion: 28 May 2030
Completion: 28 May 2030
Last update posted: 21 Aug 2026
Registered enrollment: 630
Registry id: NCT05061550

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-003369-37EU-CTR / CTIS (EudraCT)2023-508852-21-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.